Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the startup of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University. Follow Rob on Twitter @rob_cyran
- Tel: +1 646 223 6083
- E-mail: firstname.lastname@example.org
Former Morgan Stanley banker Robert Bradway runs the $109 bln biotech being eyed by activist Dan Loeb. Splitting into a cash cow and a growth arm comes up often in the industry but rarely happens. In Amgen’s case, its drug focus and the CEO’s background give the idea a chance.
The drumbeat for innovation banged on till the watch and payments technology finally appeared. In the meantime, it was iPhones that spurred better than expected revenue of $42 bln, accounting for 56 pct of the total. Apple’s one-trick pony will do until the herd picks up speed.
Turning tail on the $54 bln Shire deal exposes the U.S. drugmaker’s folly chasing a lower tax bill. Investors facing a $1.6 bln break fee should push for other AbbVie flips: boss Richard Gonzalez’s compensation and the company’s governance in the form of an independent chairman.
- IBM keeps earnings bug hardwired in system
- Cloud companies rain money on insiders
- Allergan takeover trials reach Phase III
- HP closing in on valuation problem, not its future
- Health deal's $12 bln focus on fit is promising
- GoPro lockup dump ends valuation special effect
- PayPal forced to rev after eBay's belated U-turn